Tirzepatide | Dual GIP/GLP-1 Research Peptide

AUD $200

For laboratory research use only. Not for human use.

Research-grade Tirzepatide — the dual GIP/GLP-1 receptor agonist approved as Mounjaro for type 2 diabetes and Zepbound for obesity. Studied for metabolic disease, weight management, and cardiovascular research. Third-party HPLC tested. For laboratory research use only.

Supply Specifications

PeptideTirzepatide (LY3298176)
MechanismDual GIP/GLP-1 receptor agonist
FormatLyophilised powder
Purity≥98% by HPLC
TestingThird-party HPLC + Mass Spec
Storage-20°C lyophilised
UseLaboratory research use only
PriceAUD $200

Research Summary

Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It received FDA approval as Mounjaro (type 2 diabetes) and Zepbound (obesity). In the SURMOUNT-1 trial, participants achieved approximately 22% mean body weight reduction over 72 weeks.

Tirzepatide is approved on the ARTG in Australia as Mounjaro for type 2 diabetes. Research-grade Tirzepatide from PeptideIQ is supplied for laboratory research use only, not for therapeutic use.

Related Research

  • Retatrutide vs Tirzepatide: Research Comparison
  • Peptides in Metabolic Research
  • Retatrutide Research Peptide

Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.